Milan
5-6 September 2019

Università degli Studi di Milano

1st Adult Cystic Fibrosis International Workshop

Adult Cystic Fibrosis

POSTER SESSIONS

12 EBAP credits GRANTED

13 EUROPEAN CME credits (ECMEC®S) GRANTED

AFISM
Association Internationale pour la Promotion de Formations Spécialisées en Médecine et en Sciences Biologiques

Powered by
Publi Créations

Local PCO
Lena Services Consulting Group

www.adultcysticfibrosis.org

posters sessions' schedule

Please note that each group posters are divided by topics and listed by first author's last name alphabetical order.

We kindly ask to poster presenters to stay next to their own poster for the whole duration of the poster session, in order to discuss the scientific paper with chairmen and the Workshop participants.

The presenters have been underlined in the authors's list.

POSTERS Sessions' SCHEDULE

POSTER SESSION 1 September 5th, 2019 from 15:30 to 16:00

- **Group 1:** Cystic Fibrosis Epidemiology / NTM How to deal with
- **Group 2:** Lung Transplant / ERS/ECFS Guidelines in adult patients / Transition / End of life management

POSTER SESSION 2 September 6th, 2019 from 11:00 to 11:30

- **Group 1:** Management of Infections / New Treatments for Cystic Fibrosis
- **Group 2:** Patients life management / Pregnancy in Cystic Fibrosis patients

Thursday, September 5th, 2019

15:30 - 16:00 Coffee Break & Poster Area

POSTER SESSION 1 - Group 1
Cystic Fibrosis Epidemiology
NTM How to deal with
Chairmen: S. Aliberti (Italy)
M. Shteinberg (Israel)

[1.1.1] Genetic and serum screening for alpha-1-antitrypsin deficiency in adult patients with cystic fibrosis: a single centre experience.

F. Amati[1]; A. Gramegna[1]; M. Contarini[1]; M. Pappalettera[1]; M. Seia[2]; L. Porcaro[2]; I. Ferrarotti[3]; A. Corsico[3]; S. Aliberti[1]; F. Blasi[1]
[1]Department of Pathophysiology and Transplantation, University of Milan; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Medical Genetics Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [3]Center for Diagnosis of Inherited Alpha1-antitrypsin Deficiency, Dept of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy

[1.1.2] Immunological screening in cystic fibrosis patients revealed an unexpected high prevalence of immunodeficiencies.

F. Amati[1]; A. Gramegna[1]; M. Contarini[1]; M. Pappalettera[1]; B. Vigone[2]; S. Aliberti[1]; F. Blasi[1]
[1]Department of Pathophysiology and Transplantation, University of Milan; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy

[1.1.3] Association of low BMI and fast decline of FEV1 with worse outcome in adults with CF: surveillance from a single adult centre in Slovenia

M. Badovinac[1]; D. Lestan[1]; H. Matevz[1]; M. Turel[1]; I. Kos[1]; B. Salobir[1]
[1]UKC Ljubljana, Ljubljana, Slovenia

[1.1.4] Clinical Expression of Cystic Fibrosis patients carrying the I1234V mutation

B. E. Bar Aluma[1]; D. Vilozni[1]; I. Sarouk[1]; Y. Bezalel[1]; A. Dagan[1]; S. Keler[1]; M. Ashkenazi[1]; O. Efrati[1]
[1]Sackler Medical School, Tel Aviv University, Israel

[1.1.5] Clinical characteristics and disease severity of adults with cystic fibrosis and at least one residual function mutation: a multicentric study.

M. Contarini[1]; A. Gramegna[1]; D. Savi[2,3]; F. Majo[3]; F. Ciciriello[3]; S. Schiavetto[2]; V. Lucidi[3]; P. Palange[2]; S. Aliberti[1]; F. Blasi[1]
[1]Department of Pathophysiology and Transplantation, University of Milan; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Department of Public Health and Infectious Diseases, Adult Cystic Fibrosis Center, Sapienza University of Rome, Rome, Italy; [3]Cystic Fibrosis Unit, Bambino Gesù Children's Hospital, Rome, Italy

[1.1.6] Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation: a multicentric study.

A. Gramegna[1]; M. Contarini[1]; F. Majo[2]; D. Savi[2,3]; F. Ciciriello[2]; S. Schiavetto[3]; P. Palange[3]; V. Lucidi[2]; S. Aliberti[1]; F. Blasi[1]

[1]Department of Pathophysiology and Transplantation, University of Milan; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Cystic Fibrosis Unit, Bambino Gesù Children's Hospital, Rome, Italy; [3]Department of Public Health and Infectious Diseases, Adult Cystic Fibrosis Center, Sapienza University of Rome, Rome, Italy

[1.1.7] Influence of genetic factors over low bone density in patients with cystic fibrosis in R. North Macedonia

T. Jakjovska[1]

[1]Institute for pulmonary diseases in children, Skopje, Macedonia

[1.1.8] Biofilms of Mycobacterium abscessus complex can be sensitized to antibiotics by disaggregation and oxygenation

M. Kolpen[1]; P. Østrup Jensen[1,2,3]; T. Qvist[4]; K. Nørskov Kragh[1,3]; C. Ravnholt[1]; B. Gabriel Fritz[3]; U. Rydahl Johansen[1]; T. Bjarnsholt[1,3]; N. Høiby[1,3]

[1]Department of Clinical Microbiology, Rigshospitalet, 2100 Copenhagen, Denmark; [2]Institute for inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark; [3]Costerton Biofilm Center, Institute of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [4]Copenhagen CF center, Department of Infectious Diseases, Rigshospitalet, 2100, Denmark

[1.1.9] Cystic Fibrosis diagnosis in adult life in Italy. Data from the Italian registry

R. Padoan[1] ; S. Quattrucci[2]; V. Carnovale[3]; M. Salvatore[4]; B. Giordani[5]

[1]Italian Cystic Fibrosis Registry, Roma, Italy; [2]Dipartimento Pediatria, Università Sapienza, Roma, Italy; [3]CRR Fibrosi Cistica dell'Adulto, AOU Federico II, Università di Napoli, Napoli, Italy; [4]National Center for Rare Diseases, Istituto Superiore di Sanità, Roma, Italy; [5]Lega Italiana Fibrosi Cistica - onlus, Roma, Italy

[1.1.10] Air pollution exposure is associated with lung function decrease in adults with cystic fibrosis

V. Vinnat[1] ; I. Annesi-Maesano[1]; P. Regis Burgel[2]

[1]EPAR, IPLESP, INSERM and Sorbonne Université, Medical School Saint-Antoine, Paris, France; [2]Service de pneumologie, hôpital Cochin, Paris, France

[1.1.11] Epidemiology of European adults with Cystic Fibrosis

A. Zolin[1] ; L. Naehrlich[2]; A. Fox[3]; M. Krasynk[4]; A. Orenti[1]; J. van Rens[5]

[1]University of Milan, Department of Clinical Science and Community Health, Milano, Italy; [2]Justus-Liebig-University, Department of Pediatrics, Giessen, Germany; [3]European Cystic Fibrosis Patient Registry, Verona, Italy; [4]European Cystic Fibrosis Patient Registry, Lviv, Ukraine; [5]European Cystic Fibrosis Patient Registry, Leuven, Belgium

Thursday, September 5th, 2019

POSTER SESSION 1 - Group 2
Lung Transplant
ERS/ECFS Guidelines in adult patients
Transition
End of life management
Chairmen: C. Colombo (Italy)
P. Palange (Italy)

15:30 - 16:00 Coffee Break & Poster Area

RISING STAR

[1.2.1] Lung Transplantation for Cystic Fibrosis: the Milan experience.

M. Contarini[1]; L. C. Morlacchi[1]; V. Rossetti[1]; L. Rosso[2]; M. Nosotti[2]; M. Pappalettera[1]; P. Tarsia[1]
[1]Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, Milan, Italy; [2]U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, Milano, Italy

[1.2.2] Combined Kidney–Lung Transplant under venovenous-ECMO in a Cystic Fibrosis patient

C. Dantas[1]; A. S. Santos[1]; L. Semedo[1]; P. Calvinho[2]; F. Remedio[3]; F. Nolasco[3]; J. Cardoso[1]; J. Fragata[2]
[1]Pulmonology Department - CHULC, Lisbon, Portugal; [2]Cardiothoracic Surgery Department - CHULC, Lisbon, Portugal; [3]Nephrology Department - CHULC, Lisbon, Portugal

RISING STAR

[1.2.3] Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508 del mutations

K. de Winter - de Groot[1]; G. Berkers[1]; R. van der Meer[2]; A. Vonk[1,3]; S. Michel[1]; E. Kruisselbrink[1,3] ; R. Vries[4]; H. Clevers[5]; F. Vleggaar[6]; S.Elias[7]; H.Heijerman[2,8]; K. van der Ent[1]; J. Beekman[1,3]
[1]Cystic Fibrosis Center, University Medical Center Utrecht, Utrecht, Netherlands; [2]Cystic Fibrosis Center, Haga Teaching Hospital, The Hague, Netherlands; [3]Department of Regenerative Medicine, University Medical Center Utrecht, Utrecht, Netherlands; [4]Foundation Hubrecht Organoid Technology (HUB), Utrecht, Netherlands; [5]Hubrecht Institute for Developmental Biology and Stem Cell Research, University Medical Center Utrecht, Utrecht, Netherlands; [6]Department of Gastroenterology & Hepatology, University Medical Center Utrecht, Utrecht, Netherlands; [7]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; [8]Department of Pulmonology, University Medical Center Utrecht, Utrecht, Netherlands

[1.2.4] Swiss recommendations for adult cystic fibrosis care: an open-access, point-of-care resource for adult CF centers

A. Koutsokera[1]; C. Benden[2]; J. M. Fellrath[3]; R. Fischer Biner[4]; T. Geiser[5]; M. Hofer[6]; R. Kleiner[7]; L. Nicod[1]; J. Plojoux[8]; A. Sauty[3]
[1]Lausanne University Hospital, Lausanne, Switzerland; [2]University Hospital Zurich, Zurich, Switzerland; [3]Neuchâtel Hospital, Neuchâtel, Switzerland; [4]Bern Lindenhofspital, Bern, Switzerland; [5]Bern University Hospital, Bern, Switzerland; [6]Winterthur Hospital, Winterthur, Switzerland; [7]St. Gallen Hospital, St. Gallen, Switzerland; [8]Geneva University Hospital, Geneva, Switzerland

[1.2.5] A first experience with a new patient-centered protocol for transition from pediatric to adult care for patients with cystic fibrosis

R. Lub[1] ; N. Gilst V.[1]; N. Rutjes[1]; M. Verkleij[1]; H. Eeman[1]; V. D. L. Schaaf[1]; V. M. Brederode[1]; J. Altenburg[1]
[1]Amsterdam MCD research group, dept of Pulmonary Diseases and Pediatrics of Amsterdam UMC, Amsterdam, Netherlands

[1.2.6] Adult CF patient, treating complications and management of the end life story

S. Momchilovikj[1] ; T. Jakjovska[1]; I. Arnaudova-Danevska[1]; E. Gjinovska-Tasevska[1]; A. Andonovski[1]
[1]Institute for pulmonary diseases, Skopje, Macedonia

[1.2.7] Adherence to medical regimens after lung transplantation increased using motivational interviewing and questionnaires

U. Skogeland[1] ; I. de Monestrol[1]; K. Cedermark[1]
[1]Stockholm CF-center, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

Friday, September 6th, 2019

11:00 - 11:30 Coffee Break & Poster Area

POSTER SESSION 2 - Group 1
Management of Infections
New Treatments for Cystic Fibrosis
Chairmen: F. Blasi (Italy)
V. Raia (Italy)

[2.1.1] Fungal prevalence and diversity in Stockholm CF center, a 16 years retrospective study

M. Al Shakrichi[1]; L. Klingspor[2]; L. Hjelte[1]; K. Ceder[1]; P. Bergman[3]; I. de Monestrol[1]
[1]Stockholm Cystic Fibrosis Centre, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; [2]Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden; [3]Infection Disease Clinic, The immunodeficiency Unit, Karolinska University Hospital Huddinge, Stockholm, Sweden

[2.1.2] Use of Ivacaftor in Cystic Fibrosis patients with residual function CFTR mutations

I. Bonato[1]; S. Santaniello[1]; F. Cresta[1]; R. Casciaro[1]; C. Castellani[1]
[1]Cystic Fibrosis Center, IRCCS Giannina Gaslini Institute, Genova, Italy

[2.1.3] The impact of Lumacaftor/Ivacaftor treatment on airways' microbiology

E. Bourgani[1]; C. Kosti[1]; E. Stagaki[1]; T. Panagea[2]; F. Diamantea[1]
[1]Adult Cystic Fibrosis Unit, Sismanoglio General Hospital, Athens, Greece; [2]Department of Clinical Microbiology, Sismanoglio General Hospital, Athens, Greece

[2.1.4] Role for cytokines on mucus production and attachment to the airway

M. Giorgetti[1]; A. Ermund[1]; G. Hansson[1]
[1]Department of Medical Biochemistry, University of Göteborg, Göteborg, Sweden

[2.1.5] Multidrug resistant new, previously unculturable bacterium associated with adult cystic fibrosis Chryseobacterium mucoviscidosis VT16-26

C. Kardava[1]; G. Tetz[1]; M. Vecherkovskaya[1]; T. Gembitskaia[2]; V. Tetz[1]
[1]Department of Microbiology and Virology, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation; [2]Pulmonology Research Institute, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation

[2.1.6] Lumacaftor/Ivacaftor combination in Cystic Fibrosis (CF) patients: real-life data from Verona CF Center

F. Lucca[1] ; G. Cucchetto[2]; E. Spinelli[2]; E. Pintani[2]; S. Volpi[2]
[1]Pediatrics School, University of Verona, Verona, Italy; [2]CF Center, Verona Hospital, Verona, Italy

[2.1.7] Antimicrobial susceptibility of bacteria isolated from adult patients with cystic fibrosis treated in the Institute for Pulmonary Diseases of Vojvodina Sremska Kamenica, Serbia

D. Skrbic[1] ; A. Trudic[1,2]; M. Djuric[1,2]; T. Kurucin[1]; S. Hromis[1,2]; M. Hadnadjev[1]; B. Tusek[1]; D. Povazan[1,2]
[1]Institute for Pulmonary Disesases of Vojvodina, Put Doktora Goldmana 4, 21204 Sremska Kamenica, Novi Sad, Serbia; [2]University of Novi Sad, Faculty of Medicine, Hajduk Veljkova [3], 21000 Novi Sad, Novi Sad, Serbia

[2.1.8] The effect of Lumacaftor/Ivacaftor on the severity of CF pulmonary exacerbations in patients with F508 del homozygous CF

K. Yaacoby-Bianu[1]; S. Nadeem[2]; S. Nili[3]; Z. Schnapp[4]; L. Galit[1]; M. Shteinberg[2,5]
[1]Pediatric Pulmonology Unit and CF Center, Carmel Medical Center, Haifa, Israel; [2]B. Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; [3]Department of Epidemiology and community health, Carmel Medical Center, Haifa, Israel; [4]Department of Pediatrics, Carmel Medical Center, Haifa, Israel; [5]Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel

Friday, September 6th, 2019

POSTER SESSION 2 - Group 2
Patients Life Management
Pregnancy in Cystic Fibrosis patients
Chairmen: C. Colombo (Italy)
S.Elborn (UK)

11:00 - 11:30 Coffee Break & Poster Area

[2.2.1] Doctoral thesis: Adults with cystic fibrosis: mental health and patient experiences of the CF treatment
L. Backström Eriksson[1]
[1]Karolinska Institutet, Division of psychology, Stockholm, Sweden

[2.2.2] Swedish "middle aged", non-transplanted CF-patients' experiences of their daily multifactorial treatment: a qualitative study
L. Backström Eriksson[1,2]; L. Hjelte[1,3]; B. Melin[2]; K. Sorjonen[2]; M. Lundberg[4]
[1]Karolinska University Hospital, Stockholm CF-center, Stockholm, Sweden; [2]Karolinska Institutet, Division of psychology, Stockholm, Sweden; [3]Karolinska Institutet, Division of Paediatrics, Stockholm, Sweden; [4]University of Gothenburg, Department of Health and Rehabilitation, Gothenburg, Sweden

[2.2.3] Perinatal outcomes in Cystic Fibrosis women. Data from the Italian Cystic Fibrosis Registry (ICFR)
R. Padoan[1]; A. Amato[2]; G. Barbara[2]; F. Majo[3]; S. Quattrucci[4]; M. Salvatore[5]; D. Salvatore[6]; V. Carnovale[7]
[1]Italian Cystic Fibrosis Registry, Rome, Italy; [2]Lega Italiana Fibrosi Cistica onlus, Rome, Italy; [3]CF Center, Bambino Gesù Hospital, Rome, Italy; [4]Pediatric Department Sapienza University, Rome, Italy; [5]National Center for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy; [6]CF Center, Hospital San Carlo, Potenza, Italy; [7]CRR Fibrosi Cistica dell'Adulto, AOU Federico II, Università di Napoli, Napoli, Italy

[2.2.4] Survivors Against All Odds
K. Radwan[1] ; Å. Silfverplatz[1]; A. Jarblad[1]; I. de Monestrol[2]; A. B. Brucefors[3]
[1]Swedish Cystic Fibrosis Association, RfCF, Uppsala, Sweden; [2]Stockholm CF Centre, Karolinska University Hospital, Stockholm, Sweden; [3]Retired, Previously Stockholm CF Centre, Karolinska University Hospital, Stockholm, Sweden

[2.2.5] Accelerated progression of Cystic Fibrosis lung disease during pregnancy with fatal outcome
K. Templeton[1] ; S. Thomson[1]; E. Ross[1]; J. Brennand[2]; G. MacGregor[1]; S. Bickenell[1]
[1]West of Scotland Cystic Fibrosis Service, Glasgow, United Kingdom; [2]Department of Obstetrics, Queen Elizabeth University Hospital, Glasgow, United Kingdom

[2.2.6] Pregnancy outcomes in women with Cystic Fibrosis: 10 year experience from the west of Scotland
K. Templeton[1]; E. Ross[1]; S. Thomson[1]; J. Brennand[2]; S. Bicknell[1]; G. Macgregor[1]
[1]West of Scotland Cystic Fibrosis Service, Glasgow, United Kingdom; [2]Department of Obstetrics, Queen Elizabeth University Hospital, Glasgow, United Kingdom